Elanco Animal Health (NYSE:ELAN) Reaches New 1-Year High – Here’s Why

Elanco Animal Health Incorporated (NYSE:ELAN) shares hit a new 52-week high during trading on Monday . The company traded as high as $23.17 and last traded at $23.0150, with a volume of 1331305 shares trading hands. The stock had previously closed at $22.25.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Stifel Nicolaus increased their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Piper Sandler boosted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, August 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Wednesday, November 19th. KeyCorp initiated coverage on shares of Elanco Animal Health in a report on Friday. They issued an “overweight” rating and a $27.00 price target for the company. Finally, JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their target price for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average target price of $21.56.

Elanco Animal Health Stock Up 3.8%

The firm has a market cap of $11.48 billion, a P/E ratio of 384.98, a price-to-earnings-growth ratio of 3.02 and a beta of 1.71. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average of $20.87 and a 200-day moving average of $17.11.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.13 EPS. Elanco Animal Health’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Danske Bank A S bought a new stake in Elanco Animal Health in the third quarter worth approximately $9,762,000. CANADA LIFE ASSURANCE Co boosted its stake in Elanco Animal Health by 190.0% in the third quarter. CANADA LIFE ASSURANCE Co now owns 350,334 shares of the company’s stock valued at $6,869,000 after acquiring an additional 229,519 shares during the last quarter. Woodline Partners LP lifted its position in shares of Elanco Animal Health by 15.1% during the 3rd quarter. Woodline Partners LP now owns 3,669,503 shares of the company’s stock valued at $73,904,000 after buying an additional 480,318 shares during the last quarter. Shelton Capital Management purchased a new position in shares of Elanco Animal Health in the third quarter worth about $346,000. Finally, Polymer Capital Management US LLC bought a new position in shares of Elanco Animal Health in the third quarter worth $257,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.